WntResearch Past Earnings Performance
Past criteria checks 0/6
WntResearch's earnings have been declining at an average annual rate of -9.8%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-9.8%
Earnings growth rate
50.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -271.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How WntResearch makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -44 | 45 | 0 |
| 30 Jun 24 | 0 | -41 | 42 | 0 |
| 31 Mar 24 | 0 | -36 | 37 | 0 |
| 31 Dec 23 | 0 | -32 | 33 | 0 |
| 30 Sep 23 | 0 | -31 | 31 | 0 |
| 30 Jun 23 | 0 | -30 | 30 | 0 |
| 31 Mar 23 | 0 | -30 | 30 | 0 |
| 31 Dec 22 | 0 | -31 | 30 | 0 |
| 30 Sep 22 | 0 | -38 | 37 | 0 |
| 30 Jun 22 | 0 | -38 | 38 | 0 |
| 31 Mar 22 | 0 | -39 | 38 | 0 |
| 31 Dec 21 | 0 | -36 | 35 | 0 |
| 30 Sep 21 | 0 | -28 | 28 | 0 |
| 30 Jun 21 | 0 | -25 | 25 | 0 |
| 31 Mar 21 | 0 | -21 | 20 | 0 |
| 31 Dec 20 | 0 | -22 | 21 | 0 |
| 30 Sep 20 | 0 | -23 | 23 | 0 |
| 30 Jun 20 | 0 | -26 | 25 | 0 |
| 31 Mar 20 | 0 | -27 | 27 | 0 |
| 31 Dec 19 | 0 | -25 | 25 | 0 |
| 30 Sep 19 | 0 | -29 | 28 | 0 |
| 30 Jun 19 | 0 | -27 | 26 | 0 |
| 31 Mar 19 | 0 | -25 | 25 | 0 |
| 31 Dec 18 | 0 | -24 | 24 | 0 |
| 30 Sep 18 | 0 | -20 | 19 | 0 |
| 30 Jun 18 | 0 | -22 | 21 | 0 |
| 31 Mar 18 | 0 | -30 | 29 | 0 |
| 31 Dec 17 | 0 | -35 | 34 | 0 |
| 30 Sep 17 | 0 | -34 | 33 | 0 |
| 30 Jun 17 | 0 | -31 | 30 | 0 |
| 31 Mar 17 | 0 | -25 | 25 | 0 |
| 31 Dec 16 | 0 | -20 | 20 | 0 |
| 30 Sep 16 | -11 | -29 | 18 | 0 |
| 30 Jun 16 | -5 | -25 | 20 | 0 |
| 31 Mar 16 | -3 | -20 | 17 | 0 |
| 31 Dec 15 | 0 | -18 | 18 | 0 |
| 30 Sep 15 | 14 | -4 | 18 | 0 |
| 30 Jun 15 | 11 | -4 | 15 | 0 |
| 31 Mar 15 | 10 | -7 | 17 | 0 |
| 31 Dec 14 | 8 | -7 | 15 | 0 |
| 30 Sep 14 | 8 | -6 | 14 | 0 |
| 30 Jun 14 | 5 | -6 | 11 | 0 |
| 31 Mar 14 | 4 | -4 | 8 | 0 |
| 31 Dec 13 | 5 | -4 | 9 | 0 |
Quality Earnings: K6Q0 is currently unprofitable.
Growing Profit Margin: K6Q0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: K6Q0 is unprofitable, and losses have increased over the past 5 years at a rate of 9.8% per year.
Accelerating Growth: Unable to compare K6Q0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: K6Q0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: K6Q0 has a negative Return on Equity (-271.87%), as it is currently unprofitable.